Skip to main content

Table 1 Summary of baseline characteristics of the ITT population

From: Efficacy, safety and tolerability of ongoing statin plus ezetimibe versus doubling the ongoing statin dose in hypercholesterolemic Taiwanese patients: an open-label, randomized clinical trial

  Ezetimibe
(N = 29)
Statin
(N = 34)
P-value
Age, mean (SD) 54.2 (10.9) 61.2 (10.5) 0.0277*
Height, mean (SD) 164.0 (10.3) 159.5 (9.2) 0.5549*
Weight, mean (SD) 75.0 (15.7) 71.0 (11.2) 0.0733*
Sex    
Male, n (%) 17 (58.6) 18 (52.9) 0.7999
Female, n (%) 12 (41.4) 16 (47.1) ---
Diabetes Mellitus, n (%) 14 (48.3) 16 (47.1) 0.9304*
Hypertension, n (%) 10 (34.5) 27 (79.4) 0.0007*
Coronary Artery Disease, n (%) 8 (27.6) 10 (29.4) 0.8814*
Total cholesterol, mean (SD) 213.6 (48.4) 207.3 (28.8) 0.8577*
LDL-C, mean (SD) 144.6 (45.8) 130.9 (19.4) 0.2119*
HDL-C, mean (SD) 48.4 (9.1) 52.5 (11.9) 0.1047*
Triglycerides, mean (SD) 140.3 (59.7) 158.5 (68.1) 0.3107*
ALT, mean (SD) 30.7 (12.6) 26.9 (8.1) 0.2381*
AST, mean (SD) 25.5 (7.7) 25.2 (7.8) 0.3761*
CK, mean (SD) 121. 5 (64.0) 108.0 (77.1) 0.1924*
GGT, mean (SD) 31.8 (16.5) 44.3 (32.0) 0.1318*
  1. ALT Alanine aminotransferase; AST aspartate aminotransferase, CK creatine kinase, GGT gamma-glutamyl transpeptidase; SD standard deviation.
  2. *Wilcoxon rank sum test.
  3. Chi-square test.
  4. There was one subject in the ezetimibe group with no record for gamma-glutamyl transpeptidase.